PMID- 35496952
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230402
IS  - 0971-4502 (Print)
IS  - 0974-0449 (Electronic)
IS  - 0971-4502 (Linking)
VI  - 38
IP  - 2
DP  - 2022 Apr
TI  - Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia 
      Receiving Ibrutinib Therapy.
PG  - 282-289
LID - 10.1007/s12288-021-01466-1 [doi]
AB  - Secondary hypogammaglobulinemia (SHG) is characterized by a decrease in total 
      serum immunoglobulin (Ig) levels and can lead to immunodeficiency associated with 
      recurrent and severe infections and is a common complication of chronic 
      lymphocytic leukaemia (CLL). SHG also increases with the treatment of CLL. 
      Ibrutinib is one of these treatments and acts by inhibiting bruton tyrosine 
      kinase. Twenty-seven patients with relapsed/refractory (R/R) CLL who received 
      ibrutinib monotherapy were included. IgG levels, stage, bulky disease, previous 
      treatments, genetics and laboratory features, overall survival (OS) and 
      progression free survival (PFS) were compared with and without SHG. Nine patients 
      (33.3%) had SHG and 18 patients (66.6%) didn't have SHG. The mean IgG levels 
      after ibrutinib treatment first, third, 6th and 12th months were 684, 531.3, 452 
      and 360 mg/dL respectively in SHG arm (p < 0.001) and 1156, 1058.2, 1012.8 and 
      886.9 mg/dL respectively in without SHG arm (p < 0.001). All patients with SHG 
      had ibrutinib related other adverse effects(AEs) but 2 (11.1%) patients without 
      SHG had AEs (p < 0.001). In SHG arm 7 (77.7%) had complete and partial remission 
      but in other arm only 6 (33.3%) had (p: 0.029). There was no significant 
      difference in OS and PFS (p values 0.95 and 0.64, respectively). IgG levels at 
      the beginning of ibrutinib treatment is the best predicted value for SHG 
      development in our study (p = 0.001). As a result, we reported a significant 
      decrease in IgG values after ibrutinib monotherapy in R/R CLL patients. This 
      decrease occurs every month after ibrutinib use, but after a maximum of 1 year. 
      SUPPLEMENTARY INFORMATION: The online version contains supplementary material 
      available at 10.1007/s12288-021-01466-1.
CI  - (c) Indian Society of Hematology and Blood Transfusion 2021.
FAU - Celik, Serhat
AU  - Celik S
AUID- ORCID: 0000-0002-1052-9800
AD  - Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, 
      Kayseri, Turkey. GRID: grid.411739.9. ISNI: 0000 0001 2331 2603
FAU - Kaynar, Leylagul
AU  - Kaynar L
AD  - Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, 
      Kayseri, Turkey. GRID: grid.411739.9. ISNI: 0000 0001 2331 2603
FAU - Guven, Zeynep Tugba
AU  - Guven ZT
AD  - Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, 
      Kayseri, Turkey. GRID: grid.411739.9. ISNI: 0000 0001 2331 2603
FAU - Baydar, Mustafa
AU  - Baydar M
AD  - Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, 
      Kayseri, Turkey. GRID: grid.411739.9. ISNI: 0000 0001 2331 2603
FAU - Keklik, Muzaffer
AU  - Keklik M
AD  - Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, 
      Kayseri, Turkey. GRID: grid.411739.9. ISNI: 0000 0001 2331 2603
FAU - Cetin, Mustafa
AU  - Cetin M
AD  - Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, 
      Kayseri, Turkey. GRID: grid.411739.9. ISNI: 0000 0001 2331 2603
FAU - Unal, Ali
AU  - Unal A
AD  - Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, 
      Kayseri, Turkey. GRID: grid.411739.9. ISNI: 0000 0001 2331 2603
FAU - Demirkan, Fatih
AU  - Demirkan F
AD  - Department of Hematology, Faculty of Medicine, Dokuz Eylul University, Izmir, 
      Turkey. GRID: grid.21200.31. ISNI: 0000 0001 2183 9022
LA  - eng
PT  - Journal Article
DEP - 20210703
PL  - India
TA  - Indian J Hematol Blood Transfus
JT  - Indian journal of hematology & blood transfusion : an official journal of Indian 
      Society of Hematology and Blood Transfusion
JID - 9425818
PMC - PMC9001785
OTO - NOTNLM
OT  - Bruton tyrozine kinase
OT  - Chronic lymphocytic leukemia
OT  - Hypogammaglobulinemia
OT  - Ibrutinib
OT  - Immunodeficiency
COIS- Conflict of interestThe authors report no conflict of interest.
EDAT- 2022/05/03 06:00
MHDA- 2022/05/03 06:01
PMCR- 2023/04/01
CRDT- 2022/05/02 06:56
PHST- 2020/12/03 00:00 [received]
PHST- 2021/06/25 00:00 [accepted]
PHST- 2022/05/02 06:56 [entrez]
PHST- 2022/05/03 06:00 [pubmed]
PHST- 2022/05/03 06:01 [medline]
PHST- 2023/04/01 00:00 [pmc-release]
AID - 1466 [pii]
AID - 10.1007/s12288-021-01466-1 [doi]
PST - ppublish
SO  - Indian J Hematol Blood Transfus. 2022 Apr;38(2):282-289. doi: 
      10.1007/s12288-021-01466-1. Epub 2021 Jul 3.